Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,780,614
  • Shares Outstanding, K 38,227
  • Annual Sales, $ 17,450 K
  • Annual Income, $ -135,890 K
  • EBIT $ -141 M
  • EBITDA $ -142 M
  • 60-Month Beta 1.00
  • Price/Sales 102.74
  • Price/Cash Flow N/A
  • Price/Book 7.51

Options Overview Details

View History
  • Implied Volatility 75.42% ( -4.62%)
  • Historical Volatility 46.29%
  • IV Percentile 26%
  • IV Rank 34.25%
  • IV High 135.69% on 11/27/23
  • IV Low 44.02% on 03/22/24
  • Put/Call Vol Ratio 3.33
  • Today's Volume 52
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 2.21
  • Today's Open Interest 5,774
  • Open Int (30-Day) 3,772

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 6
  • High Estimate -0.51
  • Low Estimate -0.93
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +44.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.07 +30.05%
on 10/22/24
52.99 -11.47%
on 11/14/24
+10.46 (+28.70%)
since 10/21/24
3-Month
25.14 +86.60%
on 08/22/24
52.99 -11.47%
on 11/14/24
+20.83 (+79.87%)
since 08/21/24
52-Week
15.60 +200.71%
on 12/04/23
52.99 -11.47%
on 11/14/24
+29.34 (+166.99%)
since 11/21/23

Most Recent Stories

More News
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

TARS : 46.80 (+0.47%)
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

TARS : 46.80 (+0.47%)
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

TARS : 46.80 (+0.47%)
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

TARS : 46.80 (+0.47%)
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

TARS : 46.80 (+0.47%)
2 Under the Radar Small-Cap Stocks Wall Street Analysts Think Will Double

As small-cap stocks gain traction amid a broader market rotation out of Big Tech stocks, here are two market underdogs poised for explosive growth, according to analysts.

TARS : 46.80 (+0.47%)
LUNR : 13.91 (+15.24%)
$SPX : 5,952.49 (+0.60%)
Why Shares of Tarsus Pharmaceuticals Are Up Thursday

The company's lead therapy is getting close to the finish line of FDA approval.

TARS : 46.80 (+0.47%)
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 46.80 (+0.47%)
Tarsus to Present at the Jefferies 2022 Healthcare Conference

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 46.80 (+0.47%)
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year ...

TARS : 46.80 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 49.03
2nd Resistance Point 48.20
1st Resistance Point 47.39
Last Price 46.80
1st Support Level 45.75
2nd Support Level 44.92
3rd Support Level 44.11

See More

52-Week High 52.99
Last Price 46.80
Fibonacci 61.8% 38.71
Fibonacci 50% 34.30
Fibonacci 38.2% 29.88
52-Week Low 15.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar